WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway

WEE1 inhibition modulates the efficacy of cancer immunotherapy by regulating dsRNA and interferon responses, which increases recruitment of anti-tumor T cells with concurrent PD-L1 elevation. This study provides a rationale for combination strategies between WEE1 inhibitors and anti-PD-L1 therapies. Targeted therapies represent attractive combination partners with immune checkpoint blockade (ICB) to increase the population of patients who benefit or to interdict the emergence of resistance. We demonstrate that targeting WEE1 up-regulates immune signaling through the double-stranded RNA (dsRNA) viral defense pathway with subsequent responsiveness to immune checkpoint blockade even in cGAS/STING-deficient tumors, which is a typical phenotype across multiple cancer types. WEE1 inhibition increases endogenous retroviral elements (ERVs) expression by relieving SETDB1/H3K9me3 repression through down-regulating FOXM1. ERVs trigger dsRNA stress and interferon response, increasing recruitment of anti-tumor T cells with concurrent PD-L1 elevation in multiple tumor models. Furthermore, combining WEE1 inhibition and PD-L1 blockade induced striking tumor regression in a CD8(+) T cell-dependent manner. A WEE1 inhibition-induced viral defense signature provides a potentially informative biomarker for patient selection for combination therapy with WEE1 and ICB. WEE1 inhibition stimulates anti-tumor immunity and enhances sensitivity to ICB, providing a rationale for the combination of WEE1 inhibitors and ICB in clinical trials.

Automated summary

Inhibition of WEE1 enhances the efficacy of cancer immunotherapy by regulating dsRNA and interferon responses, leading to increased recruitment of anti-tumor T cells and elevated PD-L1 levels. This study demonstrates the potential of combining WEE1 inhibitors with anti-PD-L1 therapies to improve patient outcomes and overcome resistance.